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‘targeted’ agents in current radiochemotherapy, either given 
concomitantly or as consolidation, was not successful with 
even detrimental results due to an increased toxicity and 
mortality. A lack of adequate patient selection based on the 
presence of the target biomarker may have contributed to 
these failures, as subgroup analyses suggest a benefit in 
target expressing patients. Trials are ongoing specifically 
addressing patients with stage 3 NSCLC and either an 
activating EGFR mutation or EML-ALK translocation. 2015 has 
seen the rapid implementation of immunotherapy in NSCLC 
treatment, with several monoclonal antibodies inhibiting 
checkpoint molecules showing superior outcome over 2nd line 
docetaxel. These agents will now advance in earlier stages 
and phase 3 trials with a consolidation strategy are ongoing. 
Controversial issues remain patient selection based on 
predictive biomarker expression, the combination of 
different checkpoint inhibitors and the risk of synergistic late 
pulmonary toxicity, when added to definitive thoracic 
radiotherapy. Although it is tempting to early implement 
promising new drugs in stage 3 treatment, caution should 
guide its sequencing within the radiochemotherapy 
backbone. Window of opportunity trials with induction 
treatment in biomarker selected patients will allow to 
explore the single agent activity and minimize the risk of 
additional toxicity.  
1: Bradley JD et al. Lancet Oncol 2015; 16: 187–99 
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Prostate cancer could be considered as insignificant or 
indolent (IPCa) when its presence does not bring about any 
risk for the life of the patient. If we start with this idea it is 
easy to understand that this situation is very difficult to 
predict since it depends on many variables of each patient, 
among which the life expectancy of the patient is one of the 
most important; therefore, it would seem to be a more 
theoretical question than practical, if it were not because it 
reflects an emerged reality by finding that up to 31% of the 
prostate carcinomas detected by high PSA serum levels, 
through study of the prostatectomy specimen, there were 
only small nodules of carcinoma that could have remained 
totally localized (latent) during the entire life of the patient, 
therefore they could have been treated with watchful 
waiting. It is clear that all of this supposition is a speculative 
exercise and only comes from indirect suppositions of the 
probable biology of a carcinoma node by its pathological 
characteristics. This fact explains that there are diverse 
definitions of IPCa in the radical prostatectomy specimens, 
although all coincide in requiring a small volume of tumor (< 
5cc, although there is an author that accepts < 1cc), absence 
of aggressive Gleason patterns (no 4 or 5 patterns or Gleason 
score <7) and the majority also require, for a tumor to be 
accepted as indolent, to be a confined organ tumour with 
negative margins. In accordance with these criteria, the 
prevalence of IPCa varies between 2.3% and 31%, with an 
average of 18.3%. However, this uniformity of criteria is not 
the same at the time of determining the pre-operative model 
to predict IPCa, possibly because all the studies that try to 
correlate the extension of the prostate cancer in the biopsy 
with the volume in the prostatectomy specimen show that 
this correlation is very weak; and therefore, although all the 
needle biopsy criteria for defining an IPCa require the 
absence of an aggressive Gleason pattern (pattern 4 and 5 or 
Gleason score ≤ 7) would vary as regards the extension of the 
tumor in the cores (< 3 core with no core >50% of the 
surface, only one positive core < 3mm, 1% of all the cores, no 
core > 10% of the surface) and the inclusion between the 
criteria of the PSAD (PSA density). With all this variability the 
presumption of a possible IPCa in the radical prostatectomy 
specimen of the different authors has a sensitivity of 23% to 
83.9% (average 53.2%) and a specificity of 61.9% to 99% 
(average 89.1%). Maybe it will help us to better identification 
of very low aggressive P.Ca patients the recent redefinition 
of Gleason patterns and the proposed grouping of prognostic 
grades. A new International Society Urogenital Pathology 
revision in November 2014 defined the current criteria with a 
precise definition of Gleason pattern 3 as small glands with 
variation in size and shape infiltrating amongst non neoplasic 
glands and Gleason pattern 4 according four different aspects 
as all cribriform growth (some of them previously considered 
as pattern 3), fused glands, ill defined glands and 
glomeruloid glands. But with the intention to improve the 
correlation with the clinical parameters a new grading system 
was. This new system follows the accepted the new Gleason 
patterns grouping them in five prognostic groups: Group 1 
(Gleason 3+3), Group 2 (Gleason 3+4), Group 3 (Gleason 4+3), 
Group 4 (Gleason 4+4) and Group 5 (score Gleason 9 and 10). 
According this new arrangement an excellent correlation with 
the risk of biochemical recurrence we can obtain in needle 
biopsy and radical prostatectomy specimens. 
Prostate cancer is considered insignificant (IPCa) when its 
presence does not bring any vital risk. IPCa in the radical 
prostatectomy is a small (< 5cc,), No Gleason 4 or 5, organ 
confined, negative margins. The average prevalence is 18.3%. 
The pre-operative model to predict IPCa is difficult. In the 
IPCa identification can help the new ISUP Gleason revision, 
pattern 3 small glands with variation in size and shape and 
Gleason pattern 4 according four different aspects as all 
cribriform growth, fused, ill defined and glomeruloid glands. 
A new system was accepted grouping them in five prognostic 
groups: 1 (3+3), 2 (3+4), 3 (4+3), 4 (Gs8) 5 (Gs9,10), with 
excellent clinical correlation .  
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T2-weighted MRI (T2w) typically shows a prostate cancer as a 
low signal-intensity area among the high signal-intensity 
normal peripheral zone tissue background. In the transition 
zone, prostate cancer has an equally low signal-intensity, 
although contrasting less well with the surrounding 
heterogeneous signal-intensity of glandular and stromal 
hypertrophy. It has been shown that the observed signal 
intensity inversely correlates to some extent with the 
aggressiveness of the cancer (lowest signal intensities in 
higher grade cancers). The sensitivity of T2w imaging for 
prostate cancer (of any Gleason grade) is quite high (up to 
85%), but with a low specificity (about 55%) due to many 
false positive calls. Therefore, functional imaging tools are 
required to improve the overall diagnostic accuracy.  
Diffusion-weighted MRI (DWI) is currently the most important 
functional technique in addition to T2w MRI. Its mechanism is 
based on the inhibition of spontaneous water diffusion in 
tumor areas, due to both increased cellularity (more 
hydrophobic cell membranes inhibiting water diffusion) and 
destruction of fluid-rich acini and ductules. Prostate cancers 
can hence be detected as areas of decreased signal-intensity 
on apparent diffusion coefficient (ADC) maps or as increased 
signal-intensity on high b-value images. It is more than 
noteworthy that a quite robust inverse correlation exists 
between ADC-values and tumor aggressiveness (lowest ADC-
value in higher grade cancers).  
Dynamic contrast-enhanced MRI (DCE) measures the amount 
and characteristics of tumoral neoangiogenesis. After an 
intravenous bolus injection of gadolinium-containing contrast 
media, prostate cancers tend to enhance earlier, more 
rapidly and with a more pronounced de-enhancement (wash-
out) than benign or normal tissue. DCE greatly helps 
detecting cancers in the peripheral zone, but suffers from 
false positive calls in the transition zone due to similar 
enhancement characteristics in glandular hypertrophy.  
Magnetic resonance spectroscopic imaging (MRSI) is a more 
advanced tool that currently is mainly performed in expert 
centers and in clinical trials. It is based on measurement of 
the relative concentrations of citrate and choline, markers of 
benign and malignant tissue, respectively. MRSI adds 
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specificity to T2w MRI (reduction of false-positive findings), 
but its main value lies in its direct correlation between the 
choline-to-citrate ratio and tumor aggressiveness.  
mpMRI currently more and more consists of T2w MRI 
combined with DWI. DCE is additionally performed in all 
cases by some institutions, or only in doubtful cases by 
others. Meanwhile, it remains very important that all mpMRI 
studies are performed according to uniform quality and 
reporting standards, as pointed out by the European Society 
of Urogenital Radiology Guidelines and the recently revised 
Prostate Imaging Reporting and Data System (PI-RADS version 
2). The latter consists of a diagnostic probability scale, in 
which PI-RADS 1 and 2 signify “clinically significant disease 
(highly) unlikely”, PI-RADS 3 “clinically significant disease is 
equivocal”, and PI-RADS 4 and 5 signify “clinically significant 
disease (highly) likely”. These scales are largely based on the 
unique ability of mpMRI to more easily detect high-grade and 
larger (i.e. clinically significant) tumors than small lower-
grade lesions. This holds promise in the assessment of 
patients suspected of having prostate cancer. In patients who 
are candidates for active surveillance on the basis of clinical 
parameters, a PI-RADS 1 or 2 scale can corroborate this 
choice owing to a negative predictive value for excluding 
high-grade disease up to 98%, while in patients with a PI-
RADS 4 or 5 a targeted biopsy can be performed in the 
suspicious area, including areas that are more difficult to 
reach with standard biopsy (e.g. anteriorly located tumors). 
PI-RADS 3, on the other hand, requires a biopsy in selected 
cases, taking into account clinical parameters such as PSA-
density, PSA-kinetics, patient age and potential comorbidity. 
Hence, the performance for correctly assigning patients to 
active surveillance can be increased and mpMRI is currently 
recommended at enrolment in active surveillance by the UK 
National Institute for Health and Care Excellence (NICE). 
 
SP-0106  
Active surveillance: challenges and perspectives. The 
clinician point of view 
R. Valdagni
1Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy 
1 
 
Prostate cancer (PCa) is the most common male malignancy. 
The number of diagnoses has increased since the introduction 
of the PSA in the early ‘90ies. Up to 50% of the new PCa 
detected can be considered clinically insignificant or 
indolent: this relatively new concept in oncology means that 
these very well localized, small and non aggressive tumors 
(GPS=3+3), which are generally diagnosed with a biopsy 
following PSA rises, would not cause symptoms and/or death 
during one’s life. Despite this non aggressive behavior, most 
of these tumors are still treated with curative standard 
therapies (prostatectomy, external radiotherapy and 
brachytherapy), which, although equally effective treatment 
options, are burdened by potentially severe side effects.  
As a matter of fact, there is no way to entirely distinguish 
upfront, before as well as after the biopsy, non aggressive, 
clinically insignificant, indolent tumors from aggressive, 
potentially lethal cancers that need to be treated 
immediately. To deal with the problem of overdiagnosis and 
overtreatment, active surveillance (AS) is being proposed in 
alternative to radical treatment to very selected men with 
favourable disease characteristics. AS is widely accepted in 
uro-oncologic communities and included in several 
guidelines, even if its routine application in the clinic is still 
suboptimal.  
Understanding the natural history of clinically insignificant 
PCa is of primary importance to obtain reliable tools to select 
and follow-up AS patients. AS inclusion criteria are presently 
based on ≤T2a at DRE, PSA/PSA density, number and 
percentage of positive biopy cores and GPS. Originally, the 
approach was more restrictive (i.e. selection of very low risk 
PCa patients). Nowadays, considering that feasibility and 
safety of these more strict protocols were assessed, more 
inclusive protocols are enrolling patients (e.g. including 
selected GPS=3+4).  
One of the main issues AS is currently facing is the chance of 
“inadequate” diagnoses from biopsies, known to result in 
upgrading and upstaging at prostatectomy, especially for low-
grade PCa. PSA/PSA density or the number of positive cores 
at diagnostic biopsy do not appear to be associated with the 
probability of upgrading patients initially fit for AS. This is 
the main reason to consider a confirmatory biopsy (time 
varying between 3 and 12 months) in most AS protocols, 
which can help identify patients ineligible for AS as a result 
of disease upgrading. The rate of “reclassification” at 
confirmatory biopsy varies between 16 and 30%, very similar 
to the one after prostatectomy.  
Due to its great potential, MRI is increasingly used, being able 
to identify lesions that might be missed by standard biopsy. A 
positive MRI is associated to higher upgrading rates after 
prostatectomy and also after confirmatory biopsy. At 
present, in men on AS, MRI is used as an aid to detect 
clinically significant disease and help target suspicious 
lesions; however, there is still no solid evidence to endorse 
MRI in place of repeated biopsies.  
Investigation on genetic/biomolecular/biochemical signatures 
is urgently needed to better classify our patients, trying to 
take benefit from non-invasive indicators of progression or 
reclassification. Research is currently focused on finding 
genetic signatures of both positive biopsy and adjacent 
normal tissue/stroma and on studying biomolecular markers 
possibly present in urine and blood (liquid biopsy). Recently, 
tests based on high expression of selected genes in biopsy 
specimens were found to be associated with higher risk of 
disease progression, but the possible true impact on AS is still 
to be determined.  
AS follow-up plays a crucial role, since it enables to monitor 
the tumor behavior and potentially detect the more 
aggressive forms, which may benefit from treatment. In most 
protocols, follow up is based on clinical data (DRE, PSA and 
repeat biopsies), some protocols recently including mpMRI. 
Biomarkers (e.g. PCA3 or -2proPSA) are not routinely used in 
AS protocols, due to confusing results coming from the 
literature.  
In conclusion, the results of AS programs should be primarily 
assessed on their ability to avoid overtreatment, while 
guaranteeing the same curability window of upfront radical 
treatments. The percentage of patients who remain 
treatment free is one of these measures, with current 
estimates being ≈40% at 20 years from diagnosis. Evaluation 
of oncological outcomes such as OS and CSS rates is also 
important, being in the Canadian AS cohort 62% and 94% at 15 
yrs, respectively. Secondary objectives should include 
quality-of-life and comparison of AS vs radical therapies 
costs. The variety of inclusion criteria and follow-up 
protocols makes the evaluation difficult. However, to date, 
the published outcomes are similar to those in patients 
receiving immediate curative treatment. 
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In the past 2-3 decades we have witnessed major advances of 
radiotherapy planning. These developments were based on 
implementation of sectional imaging, computerized 
treatment planning and high precision treatment 
technologies in the radiotherapy process. When compared 
with the conventional radiography based method, modern 3-4 
dimensional approaches require accurate and reproducible 
delineation of the target volume and organs at risk on the 
sectional images of various modalities, including computed 
tomography, magnetic resonance imaging, positron emission 
tomography and ultrasound. Contouring variation represents 
one of the most important contributors to the overall 
uncertainties in radiotherapy. The dosimetric and clinical 
benefits of modern high precision radiotherapy can be 
compromised by inaccurate delineation [Njeh CF. Med Phys 
2008]. Assurance of consistent and accurate contouring of the 
regions of interest is one of the main preconditions for safe 
